Contacter le RP

Pour utiliser cette fonctionnalité, vous devez bénéficier d'un compte Babbler.

arrow_back

l’outil gratuit dédié aux journalistes
Ne subissez plus l’info, maîtrisez-la

Vous pouvez vous désinscrire gratuitement. Nous utiliserons les informations que vous nous avez fournies afin de vous transmettre des contenus ciblés comme décrit dans nos Règles de confidentialité.


En vous inscrivant, vous pourrez contacter des centaines de RP dont :

Vous pouvez vous désinscrire gratuitement. Nous utiliserons les informations que vous nous avez fournies afin de vous transmettre des contenus ciblés comme décrit dans nos Règles de confidentialité.

Caroline Grangie
Leboncoin
Responsable relation médias
Manon Guignard
Uber
Communication Associate
Sheherazade Renoux
PMU
Responsable communication

Pour en savoir plus, regardez la vidéo

Vous êtes à 1 clic de l'inscription !
Qu'est-ce que Babbler ?

Précédent

Content de vous revoir !

Communiqué de presse

FDA to review Zynquista as potential treatment for type 1 diabetes
timer minutes de lecture minute de lecture

Copier le lien
Bridgewater, NJ and The Woodlands, TX – May 22, 2018 – The U.S. Food and Drug Administration (FDA) has accepted Sanofi's regulatory filing for Zynquista (sotagliflozin). The investigational oral treatment would be used in addition to insulin therapy to improve blood sugar control in adults with type
fda-to-review-zynquista-as-potential-treatment-for-type-1-diabetes-1

Cliquez sur l'image pour obtenir le format original

“If approved, Zynquista would be the first oral antidiabetic drug approved in the U.S. for use by adults with type 1 diabetes, in combination with insulin.” says Jorge Insuasty, Senior-Vice President, Global Head of Development, Sanofi.

“We look forward to working with the FDA through the review process with a view towards bringing this investigational medicine to adults with type 1 diabetes in the U.S.” Developed in partnership with Lexicon Pharmaceuticals, Inc., Zynquista is an investigational oral dual inhibitor of SGLT-1 and SGLT-2, proteins that influence how the intestines and kidneys absorb and eliminate sugar (glucose) resulting in improved glucose control and additional clinical benefits.

“After decades of little change and innovation, the treatment of type 1 diabetes has begun to shift significantly and, if approved, our dual SGLT1 and SGLT2 inhibitor, Zynquista, would be the first approved oral therapy used in combination with insulin to improve glycemic control and patient outcomes for adults in the United States who are living with type 1 diabetes,” said Pablo Lapuerta, M.D., executive vice president and chief medical officer, Lexicon.

“The acceptance of the NDA filing moves us closer to providing a meaningful option for people with type 1 diabetes and we look forward to continuing to work closely with the FDA during the review process.” The FDA New Drug Application for sotagliflozin is based on data from the inTandem clinical trial program which includes three Phase 3 clinical trials assessing the safety and efficacy of Zynquista in approximately 3,000 adults with inadequately controlled type 1 diabetes.1–3 The safety and efficacy data have not yet been evaluated by any regulatory authority.

  • Health & Medicine
  • Medicine
  • Men's Health
  • Women's Health

Autres actualités de la marque

inscrit avec succès

Félicitations, vous êtes inscrit sur BABBLER !

Pour découvrir dès maintenant toutes les actualités qui vous attendent sur Babbler, consultez votre newsfeed !

Vos domaines ont été préselectionnés. Vous pouvez les compléter en cliquant ici

  • Health & Medicine
  • Medicine
  • Men's Health